Journal
CELL ADHESION & MIGRATION
Volume 4, Issue 1, Pages 153-161Publisher
TAYLOR & FRANCIS INC
DOI: 10.4161/cam.4.1.11361
Keywords
mesothelioma; immunotherapy; immune response; cancer virotherapy; chemo-immunotherapy
Categories
Funding
- INSERM
- Ligue contre le Cancer (Ligue interregionale du Grand Ouest)
- Region Pays de Loire
Ask authors/readers for more resources
Malignant pleural mesothelioma (MPM) is a rare malignancy of the pleura with a very poor prognosis. Treatments evaluated for malignant mesothelioma, including chemotherapy, radiotherapy and surgery are of limited efficacy. However, the fact that the tumors of some patients with MPM regress spontaneously or respond to immunotherapy suggests that the immune system may respond to MPM under some circumstances. In this respect, animal studies have demonstrated immunoreactivity of MPM to different immunotherapies. In the case of MPM, several clinical studies have demonstrated a correlation between the presence of a lymphocyte infiltrate and a better prognosis and humoral response directed against specific antigens related to tumor. Thus, MPM immunotherapy is undoubtedly a highly promising but also very challenging approach to the treatment of this disease that has slipped through the defense lines of the immune system. This article reviews past and recent developments of the clinical strategies that concern immunotherapy of mesothelioma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available